Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Curcumin/doxorubicin - Immix Biopharma

Drug Profile

Curcumin/doxorubicin - Immix Biopharma

Alternative Names: Imx-110; polyphenol-curcuminoid/PEG-PE doxorubicin complex

Latest Information Update: 19 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immix Biopharma
  • Developer BeiGene; Immix Biopharma
  • Class Anthracyclines; Anti-ischaemics; Antihistamines; Antineoplastics; Antivirals; Catechols; Chemopreventatives; Cytostatic antibiotics; Doxorubicins; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Caspase 9 stimulants; Cyclo-oxygenase 2 inhibitors; Cystic fibrosis transmembrane conductance regulator modulators; DNA intercalators; HIV integrase inhibitors; Immunosuppressants; Mast cell stabilisers; NF-kappa B inhibitors; P53 gene stimulants; Phosphotransferase inhibitors; Platelet aggregation inhibitors; Protein tyrosine kinase inhibitors; STAT3 transcription factor inhibitors; Thromboxane synthase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Soft tissue sarcoma; Solid tumours
  • Preclinical Pancreatic cancer

Most Recent Events

  • 17 Jul 2023 Interim adverse events and efficacy data from a phase Ib/IIa trial in Solid tumours released by Immix Biopharma
  • 03 May 2023 Interim efficacy and adverse events data from a phase Ib/IIa IMMINENT-01 trial in Solid tumours (In children, In adults, In the elderly, Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) released by Immix Biopharma
  • 03 Feb 2023 Phase-I/II clinical trials in Solid tumours (In children, In adults, In the elderly, Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Brazil (Parenteral) (NCT05840835)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top